作者:Caroline P Owen、Paul J Nicholls、H John Smith、Rhys Whomsley
DOI:10.1211/0022357991772637
日期:2010.2.18
prostatic cancer by their inhibition of 17beta-hydroxylase:17,20-lyase (P450 17), have been extended to their selectivity against placental microsomal aromatase (P450(Arom)) in man. The compounds were 3-7-fold more potent than aminoglutethimide and had some selectivity for P450 17 as expressed by the ratio (IC50 P450(Arom))/(IC50 P450) 17)/17.0 (2), 10.3 (3), 34.6 (4) and 42.0 (5), where IC50 is the concentration
一系列1-(苯并呋喃-2-基甲基)咪唑1-5的研究先前已被扩展为通过抑制17β-羟化酶:17,20-裂合酶(P450 17)作为前列腺癌的潜在治疗药物,现已扩展到它们对人胎盘微粒体芳香化酶(P450(Arom))的选择性。该化合物的效力比氨基谷氨酰胺高3-7倍,并且对P450 17具有一定的选择性,其比率为(IC50 P450(Arom))/(IC50 P450)17)/17.0(2),10.3(3),34.6 (4)和42.0(5),其中IC50是导致50%抑制的浓度。与外消旋的α-苯基取代的化合物(6、80-1000 x氨基戊二酰亚胺)和某些外消旋的α-甲基(8.5和12.2 x氨基戊乙酰亚胺)和α-乙基(12.1)相比,P450(Arom)的1-5效力较低和32.9 x氨基戊二酰亚胺)类似物已得到合理化。